CCCC Q2 2024 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+350.7% YoY

Gross Profit

$10M83.0% margin

Operating Income

-$21M-178.6% margin

Net Income

-$18M-147.6% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+295.1%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$381M

Total Liabilities

$134M

Stockholders' Equity

$247M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$3M	+350.7%
Gross Profit	$10M	$3M	+273.9%
Operating Income	-$21M	-$38M	+42.9%
Net Income	-$18M	-$36M	+50.7%